Jaap-Jan Boelens, MD, PhD
Pediatric Hematologist-Oncologist and Bone Marrow Transplanter
Chief, Pediatric Stem Cell Transplantation and Cellular Therapies Service; Richard J. O’Reilly Chair in Honor of Kevin Zoltan Merszei
Cord Blood-Derived Cell Therapies, Rare Pediatric Blood Diseases, Lysosomal Storage Diseases, Immune-Reconstitution, and Pharmaco-Kinetics/Dynamics
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Boelens accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, University Medical Center Utrecht, Netherlands; PhD, University of Amsterdam/Academic Medical Center
Pediatrics - Leiden University Medical Center/Juliana Kinderziekenhuis, Leiden, The Hague, Netherlands
Immunology – University Medical Center Utrecht, Netherlands; Oncology – Erasmus University Medical Center, Netherlands
Pediatrics; Oncology (Netherlands)
I am a pediatric hematologic oncologist and Chief of the Pediatric Stem Cell Transplantation and Cellular Therapies Service. I specialize in bone marrow and cord blood transplantation to treat blood diseases in children and young adults. I have particular expertise caring for people with rare diseases, such as lysosomal storage disorders like Hurler’s disease and leukodystrophies like metachromatic leukodystrophy, adrenoleukodystrophy, and Krabbe disease. I am also part of a dedicated team of experts working to develop new treatments for our young patients. At MSK Kids, our goal is to better control children’s disease while improving their well-being, as well as that of their families.
Before coming to Memorial Sloan Kettering in 2018, I spent a decade developing an umbilical cord blood transplant program in the Netherlands that is now the largest in Europe. Cord blood transplants are a promising treatment for people who don’t have a suitable bone marrow match. I am continuing to build on this work by looking for ways to combine transplants with new cellular therapies. My goal is to raise the chance of eliminating disease while having less of an impact on my patients’ quality of life.
In my lab research, I feel passionate about finding better ways to help young people with blood disorders lead longer, healthier lives. We are developing advanced therapies made from cord blood that will target blood disorders at the cellular level. We are also creating mathematical models that can help us predict how a young person’s immune system will respond to these treatments. I want to take discoveries out of the lab and to the bedside to help my patients.
When I meet with patients and their families, they are often dealing with a lot of uncertainty. They have received a life-changing diagnosis and face questions about treatment, possible complications, the chance of responding to treatment, and how this experience will affect their family. I guide my patients and their families through these unknowns by giving them the time and space they need to ask me questions and process the information they hear. I try to be completely open and honest so my patients feel heard, respected, and cared for. We spend as much time together as needed to make sure this happens.
I guide my patients and their families through unknowns by giving them the time and space they need to ask me questions and process the information they hear.
Awards and Honors
- Swammerdam Prize for Innovation in Cell Therapy/Oncology, The Dutch Society of Hematology (2015)
- Clinical Trials Investigated by Dr. Boelens
- A Phase I/II Study of a New Gene Therapy for Sickle Cell Disease
- A Phase I/II Study of ECT-001-Expanded Cord Blood Transplants in Young People with Bone Marrow Cancers
- A Phase I/II Study of SMART101 in Children and Adults with Acute Leukemia Who Receive a T-Cell Depleted Stem Cell Transplant from a Donor
- A Phase II Study to See How Different Doses of Busulfan Help Improve the Immune System in Infants with Severe Combined Immunodeficiency (SCID) Having a Stem Cell Transplant
- Clinical Trials Co-Investigated by Dr. Boelens
- A Phase I Study of AMG 191 Given Before Transplant to Patients with Severe Combined Immunodeficiency (SCID)
- A Phase I Study of JCAR017 in Children with B-Cell Acute Lymphoblastic Leukemia
- A Phase I Study of UCART22 CAR T-Cell Therapy in Children and Young Adults with Recurrent or Persistent B-Cell Acute Lymphoblastic Leukemia
- A Phase II Study of CAR T-Cell Therapy in Children and Young Adults with High-Risk B-Cell Acute Lymphoblastic Leukemia with Minimal Residual Disease after Chemotherapy
- A Study of Cord Blood Transplantation in Children and Young Adults with Blood Cancers and Non-Cancerous Blood Disorders
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Admiraal R, Nierkens S, de Witte MA, Petersen EJ, Fleurke GJ, Verrest L, Belitser SV, Bredius RG, Raymakers RA, Knibbe CA, Minnema MC, van Kesteren C, Kuball J, Boelens JJ. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis. Lancet Haematol. 2017 Apr;4(4):e183-e191. doi: 10.1016/S2352-3026(17)30029-7
Admiraal R, de Koning C, Lindemans CA, Bierings MB, Wensing AM, Versluys AB, Wolfs TF, Nierkens S, Boelens JJ. Viral Reactivations and Associated Outcomes in Context of Immune Reconstitution after Pediatric Hematopoietic Cell Transplantation. J Allergy Clin Immunol. 2017 Apr 6. pii: S0091-6749(17)30571-7. doi: 10.1016/j.jaci.2016.12.992.
Admiraal R, Lindemans CA, van Kesteren C, Bierings MB, Versluys AB, Nierkens S, Boelens JJ. Excellent T-cell reconstitution and survival provided ATG exposure is low or absent after pediatric cord blood transplantation. Blood 2016 Oct 4. pii: blood-2016-06-721936. PubMed PMID: 27702800.
Admiraal R, van Kesteren C, Jol-van der Zijde CM, Lankester AC, van Tol MJ, Knibbe CA, Bredius RG, Boelens JJ. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamics cohort analysis. Lancet Haematol. 2015;2(5):e194-203
Bartelink I, Lalmohamed A, Elisabeth M van Reij, Christopher C Dvorak,Rada M Savic, Juliette Zwaveling, Robbert G Bredius, Antoine C Egberts, Marc Bierings, Peter Shaw, Christa E Nath, George Hempel, Marc Ansari,Maja Krajinovic, Yves Theoret, Michel Duval, MD; Ron J Keizer, PhD, Henrique Bittencourt, Moustapha Hassan, Tayfun Güng.r, Robert F Wynn, Paul Veys, Geoff D Cuvelier, Sarah Marktel, Robert Chiesa, Morton J Cowan, Mary A Slatter, Melisa K Stricherz, Cathryn Jennissen, Morris Kletzel, Janel R Long-Boyle, Jaap J Boelens, Association of Busulfan exposure with survival and toxicity after HCT in Children and Young Adults: a Multicenter Retrospective Cohort Analysis Lancet Hematology 2016; 10.1016/S2352-3026(16)30114-4.
Spel L, Boelens JJ, van der Steen DM et al, Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma. Oncotarget. 2015 Nov 3;6(34):35770-81.
Aldenhoven M, Wynn RF, Orchard PJ, O’Meara A, Veys P, Fischer A, Valayannopoulos V, Neven B, Rovelli A, Prasad VK, Tolar J, Allewelt H, Jones SA, Parini R, Renard M, Bordon V, Wulffraat NM, de Koning TJ, Shapiro EG, Kurtzberg J, Boelens JJ. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood 2015 Mar 26;125(13):2164-72.
Visit PubMed for a full listing of Dr. Boelens’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jaap-Jan Boelens discloses the following relationships and financial interests:
Provision of Services
Race Oncology Ltd
Provision of Services
Sanofi US Services Inc.
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.